P2X3 Modulators for Disease Treatment
According to GlobalData’s company profile on GSK, Human telomerase RT biomarker was a key innovation area identified from patents. GSK‘s grant share as of September 2023 was 45%. Grant share is based on the ratio of number of grants to total number of patents.
A recently filed patent (Publication Number: US20230312557A1) describes a compound of Formula (I) and its pharmaceutically acceptable salt or solvate. The compound is characterized by various substituents and functional groups, including X and Y as C(R2) or N, Z as a bond, CH2, or O, and R1 as hydrogen, deuterium, or various alkyl, alkenyl, alkynyl, haloalkyl, cycloalkyl, and other groups. The compound also includes R3 as hydrogen, halogen, or alkyl, and R4 as deuterium, halogen, alkyl, alkenyl, alkynyl, haloalkyl, alkoxy, or cycloalkyl. Additionally, R5, R6, R7, R8, R9, R10, R11, R12, R13, R14, and R15 are defined as various alkyl, alkyl-O-alkyl, haloalkyl, and other groups. The compound can have different structures, such as Formula (Ia’) and Formula (Ia”). The patent also claims the compound with specific characteristics, such as R1 as C1-C6haloalkyl, R3 as halogen or C1-C6alkyl, and R4 as halogen, alkyl, or alkoxy. Furthermore, the patent describes the compound’s use in pharmaceutical compositions and methods for treating disorders associated with P2X3 activity, pain, urinary tract disorders, cough, endometriosis, and endometriosis-associated symptoms. The methods may involve administering the compound alone or in combination with other therapeutic agents.
To know more about GlobalData’s detailed insights on GSK, buy the report here.
From
The gold standard of business intelligence.
Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.
Source link
#P2X3 #Modulators #Disease #Treatment